Moderna beats on revenue but loses more than expected as it scales down manufacturing

Moderna on Friday posted fourth-quarter revenue that beat estimates, but lost more than expected for the period, as the biotech company continues to slash costs and demand for its COVID vaccine falls.

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming COVID business.

Read more from CNBC.